BUZZ-Zenas BioPharma hits record high as brokerages raise PT

Reuters10-10
BUZZ-Zenas BioPharma hits record high as brokerages raise PT

** U.S. drug developer Zenas BioPharma's ZBIO.O shares rise 6.9% to record high of $27.68

** Two brokerages raise PT on ZBIO

** ZBIO signed a licensing deal worth over $2 bln with China's InnoCare 688428.SS for multiple sclerosis drug orelabrutinib on Wednesday

** Wedbush raises PT to $40 from $35

** "With an increasingly diversified pipeline, favorable licensing/royalty deals, and now two programs in phase 3 development, we would be buyers ahead of upcoming data read-outs" - Wedbush

** Jefferies raises ZBIO's PT to $43 from $35

** Think InnoCare deal is a smart move, as ZBIO now has two late-stage assets across five indications - Jefferies

** Up to last close, ZBIO's stock had risen more than threefold YTD

(Reporting by Juby Babu in Mexico City)

((Juby.Babu@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment